Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18652164 | SOLID FORMS OF ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION AND METHODS OF USE THEREOF | May 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18184077 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | March 2023 | May 2025 | Allow | 26 | 3 | 1 | No | No |
| 18162990 | PHARMACEUTICAL COMPOSITIONS CONTAINING HEMP EXTRACT FOR ADMINISTRATION TO FELINES AND RELATED METHODS | February 2023 | June 2025 | Allow | 29 | 4 | 0 | No | No |
| 18146756 | HYDRALAZINE COMPOSITIONS AND METHODS | December 2022 | June 2024 | Allow | 17 | 2 | 0 | No | No |
| 18065772 | STABLE FORMULATIONS OF SHR0302 | December 2022 | September 2024 | Allow | 21 | 3 | 0 | No | No |
| 18049952 | AQUEOUS PHARMACEUTICAL COMPOSITIONS OF PROSTAGLANDINS | October 2022 | June 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 17956553 | SK CHANNEL POSITIVE ALLOSTERIC MODULATORS | September 2022 | January 2025 | Allow | 28 | 3 | 1 | No | No |
| 17956727 | FAPI DIMER COMPOUND, FAPI DIMER-BASED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENT FOR TUMOR DIAGNOSIS, AND PREPARATION METHOD AND USE THEREOF | September 2022 | February 2024 | Allow | 17 | 2 | 0 | No | No |
| 17837619 | CRYSTALLINE FORMS OF ALDH2 MODULATORS | June 2022 | August 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17714500 | TREATMENT OF ABERRANT FIBROBLAST PROLIFERATION | April 2022 | March 2025 | Abandon | 36 | 2 | 2 | Yes | No |
| 17697281 | PURIFICATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS | March 2022 | May 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17615659 | HETEROAROMATIC ACETAMIDE DERIVATIVE, AND PREPARATION AND USE THEREOF | December 2021 | June 2025 | Allow | 42 | 1 | 1 | No | No |
| 17604732 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PARASITIC DISEASES | October 2021 | May 2025 | Allow | 43 | 1 | 1 | No | No |
| 17601790 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | October 2021 | May 2025 | Allow | 44 | 1 | 0 | No | No |
| 17441405 | COMPOUNDS FOR USE IN THE TREATMENT OF ADCY5-RELATED DYSKINESIA | September 2021 | May 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17440319 | COMPOUND AND DIAGNOSTIC SYSTEM COMPRISING SAID COMPOUND FOR THE GUSTATORY DETECTION OF INFLAMMATIONS IN THE ORAL CAVITY | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17310996 | MODULATORS OF AMPA RECEPTOR SIGNALING | September 2021 | March 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17435668 | COMPOSITION OF LANOSTEROL PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | September 2021 | April 2025 | Allow | 43 | 2 | 0 | No | No |
| 17310930 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | August 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17431634 | COMPOSITIONS COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR USE IN TREATING MENTAL DISORDERS | August 2021 | June 2024 | Abandon | 34 | 0 | 0 | No | No |
| 17400795 | PYRIDONE DERIVATIVE HAVING TETRAHYDROPYRANYLMETHYL GROUP | August 2021 | January 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17391364 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17391361 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | August 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17391620 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | August 2021 | May 2025 | Allow | 46 | 2 | 1 | No | No |
| 17425495 | CRYSTAL FORM OF 1,2,3-TRIAZOLO[1,5-A]PYRAZINES DERIVATIVE AND PREPARATION METHOD FOR CRYSTAL FORM | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17423545 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY DISEASE WITH MATRIX METALLOPROTEINASE INHIBITORS | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17416086 | THERAPIES FOR SQUAMOUS CELL CARCINOMAS | June 2021 | March 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17415681 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | June 2021 | April 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17312667 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | June 2021 | May 2025 | Allow | 48 | 2 | 0 | No | No |
| 17299463 | CRYSTALLINE FORMS OF MULTICYCLIC COMPOUNDS AND USES THEREOF | June 2021 | January 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17299438 | COMPOSITIONS AND METHODS FOR CLEANING, DECONTAMINATION AND TREATING SUBJECTS EXPOSED TO CHEMICAL IRRITANTS | June 2021 | February 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17299189 | 5-HYDROXY-7-OXABICYCLO[2.2.1]HEPTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE | June 2021 | November 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 17299164 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | June 2021 | April 2025 | Allow | 46 | 2 | 0 | No | No |
| 17309485 | COMPOSITION AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER | June 2021 | May 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17298409 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER | May 2021 | January 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17297984 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | May 2021 | June 2025 | Allow | 48 | 2 | 1 | No | No |
| 17330200 | HYDANTOIN DERIVATIVE | May 2021 | May 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17295490 | APPLICATION OF CHIDAMIDE | May 2021 | January 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17058587 | THERAPEUTIC AGENT FOR TREATING DIFFUSE GASTRIC CANCER | May 2021 | June 2025 | Abandon | 54 | 2 | 0 | Yes | No |
| 17293506 | MADRASIN-DERIVATIVE COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER | May 2021 | October 2024 | Allow | 41 | 2 | 0 | No | No |
| 17293381 | USE OF DISULFIRAM AND OTHER COMPOUNDS TO TREAT CANCERS WITH LOSS OF CHROMOSOME 16Q AND/OR LOW EXPRESSION OF METALLOTHIONEIN PROTEINS | May 2021 | May 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17288934 | NEW ALKOXYAMINOPYRIDINE DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17240969 | COMBINATION SEROTONIN SPECIFIC REUPTAKE INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST FOR REDUCING L-DOPA-INDUCED DYSKINESIA | April 2021 | December 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17287861 | Benzimidazolone Derivatives, and Analogues Thereof, as IL-17 Modulators | April 2021 | December 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 17285973 | METHODS OF TREATING CANCER WITH ARYL HYDROCARBON RECEPTOR ANTAGONISTS | April 2021 | September 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17232012 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | April 2021 | August 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17284816 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | April 2021 | October 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17284855 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | April 2021 | July 2024 | Allow | 40 | 2 | 0 | No | No |
| 17284545 | COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELLS | April 2021 | June 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17284436 | TLR7 AGONIST FOR TREATING COLORECTAL CANCER AND PHARMACEUTICAL COMBINATION THEREOF | April 2021 | September 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17226640 | LEVOKETOCONAZOLE FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA AND PRIMARY ALDOSTERONISM | April 2021 | September 2024 | Allow | 41 | 2 | 0 | Yes | No |
| 17282024 | COMBINATION PRODUCT OF A BCL-2/BCL-XL INHIBITOR AND A CHEMOTHERAPEUTIC AGENT AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | April 2021 | March 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17280267 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17209337 | COMPOSITION AND APPLICATION THEREOF AS ANTITUMOR DRUG | March 2021 | July 2024 | Allow | 40 | 2 | 0 | No | No |
| 17277099 | FULLERENES TO TREAT DISEASES AND CONDITIONS | March 2021 | January 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17274265 | BRD4-JAK2 INHIBITORS | March 2021 | April 2025 | Allow | 49 | 3 | 0 | No | No |
| 17274287 | BRD4-JAK2 INHIBITORS | March 2021 | August 2024 | Allow | 41 | 2 | 0 | No | No |
| 17273745 | CANNABINOIDS FOR THE TREATMENT OF GRAM-POSITIVE INFECTIONS INCLUDING ANTIBIOTIC-RESISTANT BACTERIAL STRAINS | March 2021 | December 2024 | Abandon | 45 | 0 | 1 | No | No |
| 17272871 | NEW CLASS OF DNA GYRASE AND/OR TOPOISOMERASE IV INHIBITORS WITH ACTIVITY AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | March 2021 | December 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 17272413 | CD47 BLOCKADE WITH PARP INHIBITION FOR DISEASE TREATMENT | March 2021 | August 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17182715 | SOLID FORMS OF BERBERINE URSODEOXYCHOLATE AND COMPOSITIONS AND METHODS THEREOF | February 2021 | July 2024 | Allow | 41 | 2 | 0 | Yes | No |
| 17269908 | BISPHOSPHONATE DRUG CONJUGATES | February 2021 | March 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17269959 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | February 2021 | April 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17156853 | ARAMCHOL SALTS | January 2021 | September 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17049162 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | October 2020 | October 2024 | Abandon | 48 | 1 | 0 | No | No |
| 16638704 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | February 2020 | June 2025 | Allow | 60 | 6 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner BRAUN, MADELINE E works in Art Unit 1624 and has examined 65 patent applications in our dataset. With an allowance rate of 66.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner BRAUN, MADELINE E's allowance rate of 66.2% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BRAUN, MADELINE E receive 1.58 office actions before reaching final disposition. This places the examiner in the 41% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BRAUN, MADELINE E is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +43.6% benefit to allowance rate for applications examined by BRAUN, MADELINE E. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 31.2% of applications are subsequently allowed. This success rate is in the 55% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 73.5% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 133.3% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 14.0% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.